NewAmsterdam Pharma (NAMS) analyst forecast and price target
Analyst forecast
Consensus of 17 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | $50.00 from $51.00 | Aug 6, 2026 |
| RBC Capital | Maintained | Outperform | $51.00 from $47.00 | Jun 30, 2026 |
| Guggenheim | Maintained | Buy | $45.00 from $41.00 | Feb 19, 2026 |
| Needham | Maintained | Buy | $48.00 from $46.00 | Feb 18, 2026 |
| RBC Capital | Maintained | Outperform | $47.00 from $44.00 | Jan 21, 2026 |
| Stifel | Maintained | Buy | $50.00 from $44.00 | Dec 16, 2025 |
| Goldman Sachs | Maintained | Neutral | $37.00 from $30.00 | Dec 2, 2025 |
| RBC Capital | Maintained | Outperform | $44.00 from $39.00 | Nov 6, 2025 |
| Needham | Maintained | Buy | $46.00 from $40.00 | Nov 5, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $52.00 | Oct 20, 2025 |
| Citigroup | Maintained | Buy | $50.00 from $42.00 | Oct 17, 2025 |
| Wells Fargo | Initiated Coverage | Overweight | $45.00 | Aug 25, 2025 |
| RBC Capital | Maintained | Outperform | $39.00 from $38.00 | Aug 7, 2025 |
| Goldman Sachs | Initiated Coverage | Neutral | $27.00 | Jul 17, 2025 |
| Citigroup | Initiated Coverage | Buy | $42.00 | Jun 17, 2025 |
| Needham | Maintained | Buy | $40.00 | Jun 12, 2025 |
| Stifel | Initiated Coverage | Buy | $44.00 | Jun 10, 2025 |
| Needham | Maintained | Buy | $40.00 from $42.00 | May 8, 2025 |
| Needham | Maintained | Buy | $42.00 | Apr 8, 2025 |
| Needham | Maintained | Buy | $42.00 from $46.00 | Feb 27, 2025 |
Frequently asked questions
Is NAMS a buy, sell, or hold?
Analysts covering NewAmsterdam Pharma currently average a Buy rating: 16 buy, 1 hold and 0 sell, from 17 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on NAMS?
On Aug 6, 2026, RBC Capital maintained NewAmsterdam Pharma at Outperform with a price target of $50.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.